Bumetanide and Injectafer drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Bumetanide (bumetanide) and Injectafer (ferric carboxymaltose). Common drug interactions include rash among females and neutropenia among males.

The phase IV clinical study analyzes what interactions people have when they take Bumetanide and Injectafer. It is created by eHealthMe based on reports of 14 people who take the same drugs from the FDA, and is updated regularly.

What is Bumetanide?

Bumetanide has active ingredients of bumetanide. It is often used in fluid retention. eHealthMe is studying from 20,532 Bumetanide users. Check the latest studies of Bumetanide.

What is Injectafer?

Injectafer has active ingredients of ferric carboxymaltose. eHealthMe is studying from 3,270 Injectafer users. Check the latest studies of Injectafer.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Sep, 03, 2026

14 people who take Bumetanide and Injectafer together, and have interactions are studied.

Bumetanide and Injectafer drug interactions.

What are the common drug interactions of Bumetanide and Injectafer, by gender? *:

female:

Rash
Gait disturbance
Oedema (fluid collection in tissue)
Peripheral swelling
Arthropod sting (arthropod bite)
Infusion site haemorrhage (bleeding from infusion site)
Dermatitis contact (skin reaction (dermatitis) resulting from exposure to allergens)
Dyspnoea (difficult or laboured respiration)
Hypersensitivity
Malaise (a feeling of general discomfort or uneasiness)

male:

Neutropenia (an abnormally low number of neutrophils)
Respiratory tract infection
Thrombocytopenia (decrease of platelets in blood)

What are the common drug interactions of Bumetanide and Injectafer, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

n/a

40-49:

n/a

50-59:

Chest pain
Influenza
Infusion related reaction
Meningitis aseptic (a condition that causes the membranes covering your brain and spinal cord to become inflamed)
Muscular weakness (muscle weakness)
Rash
Gait disturbance
Oedema (fluid collection in tissue)
Peripheral swelling
Arthropod sting (arthropod bite)

60+:

Nausea (feeling of having an urge to vomit)
Neutropenia (an abnormally low number of neutrophils)
Respiratory tract infection
Thrombocytopenia (decrease of platelets in blood)
Vomiting
Back pain
Musculoskeletal pain (pain affects the bones, muscles, ligaments, tendons, and nerves)
Pain in extremity

What are the existing conditions these people have? *

Chronic Inflammatory Demyelinating Polyradiculoneuropathy (long lasting infection of nerves outside brain and spinal cord): 8 people, 57.14%
Polyneuropathy (neurological disorder that occurs when many peripheral nerves throughout the body malfunction simultaneously): 5 people, 35.71%
Primary Pulmonary Hypertension (primary high blood pressure that affects the arteries in the lungs and the right side of your heart): 3 people, 21.43%
Anaemia (lack of blood): 2 people, 14.29%
Oedema Peripheral (superficial swelling): 1 person, 7.14%
Neoplasm Malignant (cancer tumour): 1 person, 7.14%
Nausea (feeling of having an urge to vomit): 1 person, 7.14%
Multiple Myeloma (cancer of the plasma cells): 1 person, 7.14%
Iron Deficiency Anaemia: 1 person, 7.14%
Infection: 1 person, 7.14%

* Approximation only. Some reports may have incomplete information.

Do you take Bumetanide and Injectafer?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously